← Back

Wire · opportunities

Revolution Medicines Drugged a Target Scientists Called “Undruggable” for Decades. Buy ...

Published

20 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at theglobeandmail.com →

◆ Verified

Fusion42 · 21 November 2026 · Fusion42 review

Revolution Medicines launched Rasonque, a novel oncology drug targeting RAS-addicted cancers, showing strong Phase 3 results and generating $198 million in revenue within five weeks. The drug's success signals a breakthrough against previously 'undruggable' cancer targets, with the company running multiple Phase 3 trials and poised for significant revenue growth.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You now face a new competitor in pancreatic cancer treatment that has drastically improved survival rates. Your moves this week should consider how Rasonque's success could reroute patient demand and redefine treatment standards.

◆ Coverage

1 source · 20 Nov 2026

◆ Related on Wire

◆ Topics

Biotechoncologydrug-launchclinical-trialsRAS-targetbiotech-market